November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Blood Test Approach Evaluates Long-Term Risk of Cognitive Decline

🧠 AI Analysis 2 min read 👁 3

A recent study published in JAMA Neurology demonstrates how measuring a specific blood protein, combined with age and genetic data, can estimate an individual's probability of developing cognitive impairment over a decade.

Blood Test Approach Evaluates Long-Term Risk of Cognitive Decline🧠AI Analysis

Photo: Medical Xpress

Key points

  • Blood test evaluates p-tau217 levels to estimate future cognitive decline risk.
  • Method combines biomarker data with age, sex, and APOE e4 status.
  • Study analyzed over 2,000 cognitively healthy older adults.

Investigators at the Mayo Clinic have developed a method to calculate a person's individual likelihood of experiencing mild cognitive impairment or dementia within five to ten years. Reported in JAMA Neurology, the procedure evaluates levels of phosphorylated Tau 217 (p-tau217)—a protein fragment linked to Alzheimer's pathology—alongside demographic factors including age, sex, and the presence of the APOE e4 genetic variant.

To establish these calculations, researchers examined data from 1,644 cognitively healthy participants in the Mayo Clinic Study of Aging and validated their findings using information from 534 individuals in the Alzheimer's Disease Neuroimaging Initiative. The cohorts included adults aged 60 to 90 who underwent biomarker testing and regular mental assessments. The investigation revealed that elevated p-tau217 concentrations and advanced age strongly correlated with a higher probability of future cognitive deterioration. For instance, calculations showed that a 75-year-old female without the high-risk gene variant faced a 5% five-year risk with low biomarker levels, whereas her risk climbed to 16% when biomarker concentrations were higher.

While the methodology offers a more nuanced interpretation than a simple positive or negative screening result, authors emphasize limitations. The framework was created predominantly from specific study populations, meaning further validation is required across more diverse demographic groups and using alternative laboratory assays. At present, professional guidelines do not advise routine biomarker screening for asymptomatic individuals.

What to know: Researchers integrated blood biomarker measurements with age and genetics to quantify long-term cognitive decline risk, though experts stress the method requires additional validation in diverse populations before clinical application. Always consult a qualified physician regarding personal medical decisions.

Source Medical Xpress — medicalxpress.com/news/2026-11-alzheimer-blood-marker-cognitive-impairm… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.